CClinicalTrials.gg
Status unknownNCT04359940Updated Apr 24, 2020

Effect of Contouring Techniques on CMR Assessment of the Right Ventricle in Repaired Tetraology of Fallot

An observational study in Tetralogy of Fallot, sponsored by University Hospital Birmingham NHS Foundation Trust. Status unknown at 2 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by University Hospital Birmingham NHS Foundation Trust · Observational

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients with repaired tetralogy of Fallot (RTOF) develop chronic pulmonary regurgitation and require monitoring for right ventricular dilatation. Pulmonary valve replacement can prevent irreversible right ventricular (RV) dilatation and dysfunction and cardiac magnetic resonance (CMR) is used to facilitate its optimal timing. The investigators sought to determine whether the choice of myocardial contouring technique affects preoperative RV volumetric thresholds for intervention.

Read the detailed description

Participants with repaired tetralogy of Fallot (RTOF) will be identified using existing patient electronic records who have developed chronic pulmonary regurgitation and are undergoing monitoring for right ventricular dilatation. Cardiac magnetic resonance (CMR) is used to facilitate its optimal timing. Pulmonary valve replacement can prevent irreversible right ventricular (RV) dilatation and dysfunction and cardiac magnetic resonance (CMR) is used to facilitate its optimal timing. There are different post-processing techniques published for measuring RV volumes on cardiac magnetic resonance imaging (detailed vs. smoothed and manual vs. automated). The primary aim of this study is to identify whether the choice of myocardial contouring technique affects the preoperative RV volumetric thresholds for intervention. As a secondary aim, the investigators will determine the reproducibility of different contouring methods.

02

Conditions studied

  • Tetralogy of Fallot

Browse trials for

03

In context

Tetralogy of Fallot

93 studies on the registry are indexed under Tetralogy of Fallot; 26 are open to participants now.

This study's planned enrollment of 30 is below the median of 120 across 39 observational studies indexed under Tetralogy of Fallot.

Browse Tetralogy of Fallot studies →

Lead sponsor

University Hospital Birmingham NHS Foundation Trust is the lead sponsor of 35 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with repaired tetralogy of Fallot (RTOF) with chronic pulmonary regurgitation who require monitoring for right ventricular dilatation.

Inclusion criteria

  • Consecutive patients with repaired Tetralogy of Fallot undergoing routine clinical surveillance at a Level 1 ACHD surgical referral centre.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Repaired Tetralogy of Fallot

    Patients undergoing routine clinical aand CMR surveillance

    Diagnostic Test: Cardiac MRI

Interventions

  • Diagnostic testCardiac MRI

    For clinical surveillance

06

What researchers measure

Primary outcomes

  1. Difference in the baseline measurement of indexed right ventricular end-diastolic volume according to the contouring technique

    Measurements of indexed right ventricular end-diastolic volume will be repeated using different contouring techniques on the same cardiac MRI study performed at baseline pre-surgery.

    Time frame: Cross-sectional study. Repeated measurements performed on the baseline CMR study.

07

Study locations

2 of 2 sites recruiting
  • QEHB
    Birmingham, B15 2TH, United Kingdom
    Recruiting
  • Cardiac MRI department, University Hospitals Birmingham NHS Foundation Trust
    Birmingham, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04359940
Lead sponsor
University Hospital Birmingham NHS Foundation Trust
Responsible party
William E Moody (Consultant Cardiologist, University Hospital Birmingham NHS Foundation Trust) — Principal investigator
First posted
Apr 24, 2020
Start date
Jan 1, 2013
Primary completion
Apr 14, 2020
Completion
Apr 14, 2020 (estimated)
Last update
Apr 24, 2020

Study contacts

Freya Lodge
Contact
freya.lodge@uhb.nhs.uk
William Moody
Contact
william.moody@nhs.net
William Moody
principal investigator · UHB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion